Steven T. Chen

Steven T. Chen

Auto-generated profile, based on publicly available information

Steven T. Chen

The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Science Translational Medicine
Verified
Journal Article
Open access
SCSteven T. Chen
Steven T. Chen
MPMatthew Park
Matthew Park
DVDiane Marie Del Valle
Diane Marie Del Valle
MBMark Buckup
Mark Buckup
ATAlexandra Tabachnikova
Alexandra Tabachnikova
MMMiriam Merad
Miriam Merad
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue–resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.

3 February 2025 in Kidney360
Verified
Journal Article
Open access
PJPushkala Jayaraman
Pushkala Jayaraman
MRMadhumitha Rajagopal
Madhumitha Rajagopal
IPIshan Paranjpe
Ishan Paranjpe
MSMayte Suarez-Farinas
Mayte Suarez-Farinas
LLLora E. Liharska
Lora E. Liharska
Girish N. NadkarniGirish N. Nadkarni
Girish N. Nadkarni
Key Points: AKI in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is linked to mitochondrial dysfunction and cellular stress, highlighting novel biomarkers for severe AKI. Molecular similarities between AKI in SARS-CoV-2 and sepsis suggest that current therapeutic strategies may be applicable across both conditions. Molecular changes in acute SARS-CoV-2 infection are tied to long-term inflammation, immune dysregulation, and lasting cardiac and renal dysfunction. Background: AKI is common in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019, often leading to long-term kidney dysfunction. However, the transcriptomic features of AKI severity and its long-term effects are underexplored. Methods: We performed bulk RNA sequencing on peripheral blood mononuclear cells from hospitalized patients with SARS-CoV-2 infection and complemented these findings with proteomic data from the same cohort. We compared the functional enrichment findings with historical sepsis–AKI data and subsequently examined the association between molecular signatures and long-term kidney function changes. Results: In 283 patients, 57 had mild AKI (stage 1) and 49 had severe AKI (stage 2 or 3). After adjustments for age, sex, severity of infection, and preexisting CKD, we identified 6432 differentially expressed genes in the severe AKI versus control comparison, 840 in the mild AKI versus control comparison, and 1213 in the severe versus mild AKI comparison (false discovery rate <0.05). Common pathways included unfolded protein response, cellular response to stress using eIF2, and IFN-γ–mediated inflammatory response. Severe AKI was linked to pathways involved in mitochondrial dysfunction and endoplasmic reticulum stress. Proteomic analysis confirmed 40 established AKI and inflammation biomarkers, whereas gene-set enrichment of transcription regulators revealed additional biomarkers for severe AKI. Comparison with peripheral blood mononuclear cell transcriptomics from sepsis-related AKI showed significant functional overlap (30%). Analysis of postdischarge eGFR data in 115 patients identified 177 differentially expressed genes for severe AKI versus control, 106 for mild AKI versus control, and 46 for severe versus mild AKI. Key associations included kidney function decline related to carbohydrate and mitochondrial metabolism, inflammatory-response, and cardiovascular regulation. Conclusions: We demonstrate that severe AKI in SARS-CoV-2 infection is linked to mitochondrial dysfunction and endoplasmic reticulum stress. The functional overlap with sepsis–AKI suggests potential broader therapeutic applicability. Long-term kidney dysfunction is influenced by disruptions in cellular energy metabolism and immune response.